Join
Live feed
·
NEWSReleasevia Quantisnow
Moderna Inc. logo

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

ByQuantisnow·Wall Street's wire, on your screen.
MRNA· Moderna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRNA (Moderna Inc.) and more on Quantisnow.